OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS

Documenti analoghi

• 3-STEP TAQMAN RT-PCR: ULTIMATE MESSENGER RNA DETECTION SENSITIVITY FOR CF GENE THERAPY CLINICAL TRIALS
  di: McCormick, D, et al.
  Pubblicazione: (2009)
• Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes.
  di: Davies, L, et al.
  Pubblicazione: (2008)
• EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
  di: Davies, J, et al.
  Pubblicazione: (2009)
• REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
  di: Alton, E, et al.
  Pubblicazione: (2012)
• Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
  di: Alton, E, et al.
  Pubblicazione: (2012)